ReviewTherapeutic innovation & regulatory science2026
Current Status and Construction Requirements of Drug Clinical Trial Institutions in Sichuan Province in China.
Review in Therapeutic innovation & regulatory science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This paper aims to systematically analyze the distribution, capacity status, and development trends of drug clinical trial institutions in Sichuan Province, and explore future construction directions and core requirements. A descriptive quantitative research design was adopted, including descriptive statistical analysis of national and provincial filing data, trend analysis of institutional development, and supplementary policy document review. The situational analysis indicates that Sichuan's drug clinical trial institutions exhibit a pattern of "high concentration in core areas and multi-point development in other regions": 50.6% of institutions are concentrated in Chengdu, while 5 prefecture-level cities still lack qualified institutions. This study has three distinct contributions: First, it is the first systematic analysis of Sichuan's drug clinical trial institutions based on post-2019 filing system data, revealing regional and professional disparities; Second, it proposes a "1 + N" regional collaborative construction framework tailored to western China's characteristics; Finally, it provides actionable policy recommendations for institutional quality improvement under strict regulatory requirements. From the perspective of development potential, future construction priorities should shift from "quantitative expansion" to "qualitative leap," comprehensively enhancing institutional capabilities through standardization, specialization, and digitalization. These improvements are expected to better undertake national major new drug development tasks, empower high-quality development of the biomedical industry, and may serve as a reference for gradually improving patient access to innovative treatments in the long term.
Indexed as
Identifiers
42373933What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.